Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
celgene
Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.
Celgene Acquires Gloucester In $340M Deal
Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
FDA to Review Alternative Dosing Method for Bone Marrow Drug
Most people have never heard of myelodysplastic syndrome (MDS), but approximately 10,000 to 15,000 people in the U.S. are diagnosed with it every year.
Burrill Report: Financing Activity May Lift Cloud Hanging Over Biotech Industry
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.